Merck's Keytruda (pembrolizumab), an anti-PD-1 immune checkpoint inhibitor, failed to demonstrate a statistically significant improvement in recurrence-free survival (RFS) in the KEYNOTE-937 Phase 3 trial, which evaluated its use as adjuvant therapy in patients with hepatocellular carcinoma (HCC) who underwent surgery and local ablation and achieved a complete radiological response. Presented at the 2026 ASCO GI Symposium, the third interim analysis revealed a median RFS of 46.7 months for the Keytruda arm, compared to 45.5 months for the placebo arm, a difference that was not statistically significant. The hazard ratio (HR) was 1.06 (95% confidence interval [CI] 0.88-1.26, p=0.719), indicating that the survival curves for the two groups were nearly identical. Consequently, the study was terminated without conducting a formal statistical analysis of the other primary endpoint, overall survival (OS). This suggests that immunotherapy alone may not be sufficient to demonstrate efficacy in preventing recurrence in patients with early-stage HCC after surgery.

The market for adjuvant therapy for HCC has been a challenging one. Despite the high recurrence rate (approximately 70% within 5 years) after curative treatments such as surgery or resection, there has been a significant unmet need for an effective standard of care (SoC) to prevent recurrence. Many global pharmaceutical companies have attempted to enter this market, but the failure of Keytruda further highlights the complexities and challenges of developing adjuvant therapies for HCC. The liver's unique characteristics, including chronic inflammation and an immunosuppressive environment, likely contribute to the difficulty of achieving complete control of tumor recurrence with a single immune checkpoint inhibitor. This result has led to a growing consensus in the clinical community that more potent combinations or multi-faceted treatment approaches are needed, rather than single-agent immunotherapy.

The failure of Keytruda, coupled with the mixed results from Roche's IMbrave050 trial (atezolizumab and bevacizumab), has sent shockwaves through the industry. While Roche's combination therapy initially showed promising RFS improvements in an interim analysis, updated long-term follow-up data revealed that the RFS benefit was not sustained, raising concerns about its long-term market dominance. As a result, both Merck and Roche have failed to fully penetrate the adjuvant HCC market, leaving the estimated multi-billion dollar global HCC adjuvant therapy market still up for grabs. This has further intensified interest in the upcoming results of BMS's Opdivo (nivolumab) trials, both as a single agent and in combination.

From the perspective of bio-sector investors and venture capitalists (VCs), Merck's failure to expand the indication for Keytruda is likely to be seen as a short-term headwind, potentially slowing down the company's portfolio diversification efforts. However, in the long term, the clear limitations of single-agent immunotherapy in the adjuvant HCC setting may create opportunities for investment in innovative combination therapies or novel targets. Companies with promising pipelines of combination therapies or new drug candidates that address the complex tumor microenvironment (TME) are likely to become attractive partners for future collaborations.

Investors are now likely to focus on precision-based companies that can demonstrate synergistic effects and long-term survival benefits with combination therapies, rather than relying solely on single-agent immune checkpoint inhibitors.